Chargement des cours...
Prévisions
| Acheter |
3 |
| Conserver |
5 |
| Vendre |
1 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Roche: lung cancer candidate Divarasib outperforms approved therapies in study
In a registration-relevant head-to-head trial against Lumakras (Amgen) and Krazati (Mirati Therapeutics), Divarasib achieved significant improvements in progression-free survival and overall survival. No new safety signals were observed. Roche plans to submit the data to regulators and present the results at a medical congress. » Plus sur finanzen.net
Roche: FDA accepts Roche's approval application for Giredestrant for review
The FDA has accepted the approval application for Roche's drug candidate Giredestrant for review. This brings a potential U.S. approval for Giredestrant one step closer. Further regulatory steps and decisions remain pending. » Plus sur finanzen.net
Roche announces new data on obesity portfolio
Roche has announced the release of new data from its obesity portfolio. Details on study results or timelines were not mentioned in the text, and investors are awaiting further information on the efficacy and regulatory approval prospects of the treatments. » Plus sur finanzen.net
Roche licenses flu drug Xofluza to generics manufacturers for 129 countries
Roche and the UN‑backed organization Medicines Patent Pool have signed a voluntary licensing agreement for the flu medicine Xofluza aimed at low‑ and middle‑income countries. The goal is to improve supply during seasonal outbreaks and potential pandemics; generics manufacturers may develop, produce and distribute the drug in 129 countries. Roche will provide a core data package, reference products for bioequivalence studies and required regulatory approvals, but sublicensees must handle the approval processes themselves. » Plus sur finanzen.net
Roche: Tecentriq receives US approval for muscle-invasive bladder cancer
The cancer immunotherapy Tecentriq (Atezolizumab) was approved in the US as an adjuvant therapy for patients with muscle-invasive bladder cancer after bladder removal, when molecular tests detect residual disease. The approval is the eleventh indication for Tecentriq in the US and is based on phase-III trials that reduced relapse rates and the risk of death. In 2025 Tecentriq generated sales of 3.6 billion Swiss francs. » Plus sur finanzen.net
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursDonnées financières de l'entreprise
| (EUR) | juin 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 32,71 Md | - |
| Bénéfice brut | 24,11 Md | - |
| Bénéfice net | 7,4 Md | - |
| EBITDA | 10,17 Md | - |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 303,27 Md € |
Nombre d'actions | 688,93 M |
Plus haut/bas sur 52 semaines | 454,70 € - 324,62 € |
Rendement du dividende | 2,45 % |
Dividendes TTM | 10,81 € |
Bêta | 0,35 |
Ratio P/E | 26,65 |
Ratio PEG | 0,90 |
Ratio P/B | 10,13 |
Ratio P/S | 4,64 |
Profil de l'entreprise
| Nom | Roche PS |
| PDG | Thomas Schinecker |
| Siège social | Basel,
Suisse |
| Site web | |
| Secteur | Santé |
| Industrie | Produits pharmaceutiques |
| Employés | 103 249 |